positive ion mode. Data processing: XCMSonline (peak alignment), MetaboAnalyst (statistics) and Mummichog (pathways). Partial least squared discriminant analysis (PLS-DA) was performed to detect differences in the four groups: GDM visit 1, GDM visit 2, GT visit 1, GT visit 2. RESULTS: Of 65 patients with 2 samples, 30 (46%) had GDM. Women with GDM were significantly more likely to be Hispanic; GT women were mostly black (p<0.01). GDM samples were obtained at a slightly later gestational age (27.5 vs 26.0 wks, p<0.001). Overall, distinct differences were seen between GT and GDM groups. Although there were some variation in metabolomics over a 3-7 day period, several analytes of interest that can be used to distinguish GDM from GT remained stable over a 3-7 day period (Figure 1) . Random forest plots demonstrate the samples separating based on GDM, not visit. Pathway analysis demonstrated differences in ascorbate, amino acid, and glycerophospholipid metabolism between GDM and GT; these pathways were not identified in differences between visits. CONCLUSION: The metabolomics profile at 24-28 wks can distinguish GDM and is reproducible over a 3-7 day period. Further exploration of the specific metabolites and the possibility of using combinations of these metabolites to diagnose GDM should be explored further. Patients with GDM were randomized to use either real-time or blinded CGM. The blinded CGM group wore a CGM system that only collected, but did not display data. The realtime CGM group wore a CGM system that collected and displayed continuous glycemic feedback. Both groups also completed SMBG 4-7 times daily. The primary outcome was mean sensor glucose level during the fourth week of CGM use. Secondary outcomes included time spent in and out of a glycemic target of 70-140 mg/dL, polyhydramnios, macrosomia, and a composite of obstetric and neonatal outcomes. Sample size calculations were designed to detect a 20% decrease in mean glucose level with 80% power. RESULTS: From December 2017 through May 2018, a total of 374 patients diagnosed with GDM were referred to our practice. Of these, 40 met inclusion criteria and were enrolled. Twenty patients were randomized into the blinded CGM group and 20 into the realtime CGM group. Twelve (60%) patients in the blinded CGM group and 11 (55%) in the real-time CGM group completed 4 weeks of monitoring and were included in the final analysis. Demographic characteristics were similar between groups. There was no significant difference in mean sensor glucose level between the blinded CGM group (98.9+8.9 mg/dL) and the real-time CGM group (107.5+11.4 mg/dL) in the fourth week of CGM use. There were also no significant differences in time spent in glycemic target, maternal, or neonatal outcomes. An end of participation survey showed that all study patients would consider CGM to monitor glucose in a subsequent pregnancy and all patients in the real-time CGM group believed that the real-time feedback was helpful in managing their GDM. CONCLUSION: Our study showed that the feedback provided by realtime CGM did not significantly decrease mean glucose values compared to SMBG alone after four weeks of CGM use. All patients considered CGM an effective motivational tool for use in GDM.
85 Real-time continuous glucose monitoring in gestational diabetic pregnancies: a randomized controlled trial Andrew Lane, Malgorzata Mlynarczyk, Margarita de Veciana, Alfred Abuhamad
Eastern Virginia Medical School, Norfolk, VA OBJECTIVE: To evaluate whether real-time continuous glucose monitoring (CGM) improves glycemic control over intermittent self-monitoring of blood glucose (SMBG) in gestational diabetes (GDM). STUDY DESIGN: This represented a randomized controlled trial at a single academic institution. Patients with GDM were randomized to use either real-time or blinded CGM. The blinded CGM group wore a CGM system that only collected, but did not display data. The realtime CGM group wore a CGM system that collected and displayed continuous glycemic feedback. Both groups also completed SMBG 4-7 times daily. The primary outcome was mean sensor glucose level during the fourth week of CGM use. Secondary outcomes included time spent in and out of a glycemic target of 70-140 mg/dL, polyhydramnios, macrosomia, and a composite of obstetric and neonatal outcomes. Sample size calculations were designed to detect a 20% decrease in mean glucose level with 80% power. RESULTS: From December 2017 through May 2018, a total of 374 patients diagnosed with GDM were referred to our practice. Of these, 40 met inclusion criteria and were enrolled. Twenty patients were randomized into the blinded CGM group and 20 into the realtime CGM group. Twelve (60%) patients in the blinded CGM group and 11 (55%) in the real-time CGM group completed 4 weeks of monitoring and were included in the final analysis. Demographic characteristics were similar between groups. There was no significant difference in mean sensor glucose level between the blinded CGM group (98.9+8.9 mg/dL) and the real-time CGM group (107.5+11.4 mg/dL) in the fourth week of CGM use. There were also no significant differences in time spent in glycemic target, maternal, or neonatal outcomes. An end of participation survey showed that all study patients would consider CGM to monitor glucose in a subsequent pregnancy and all patients in the real-time CGM group believed that the real-time feedback was helpful in managing their GDM. CONCLUSION: Our study showed that the feedback provided by realtime CGM did not significantly decrease mean glucose values compared to SMBG alone after four weeks of CGM use. All patients considered CGM an effective motivational tool for use in GDM.
Oral Concurrent 7 MEDICAL COMPLICATIONS ajog.org OBJECTIVE: The investigational, positive allosteric modulator of ɣ-aminobutyric acid A (GABA A ) receptors, brexanolone iv (BRX), was evaluated for efficacy and safety in women with postpartum depression (PPD) in 3 double-blind, placebo-controlled, randomized trials. BRX met the primary efficacy endpoint with a significantly greater change from baseline in Hamilton Rating Scale for Depression (HAM-D) total score at Hour 60 than placebo (PBO). This abstract presents the results of a secondary measure, the Montgomery-Åsberg Depression Rating Scale (MADRS). STUDY DESIGN: An umbrella protocol for the 3 studies allowed integrated dataset analysis. Women aged 18-45 years, 6 months postpartum, with PPD (i.e. major depressive episode no earlier than third trimester and no later than 4 weeks post-delivery) and a qualifying 17-item HAM-D total score ( 26 in Studies A and B; 20-25 in Study C) were enrolled. Randomized subjects received a single,
